Allogeneic transplant in multiple myeloma: who should receive it and the future of transplant
Heinz Ludwig et al.
The importance of minimal residual disease in ALL
Myeloma 2016: Panel discussion on novel treatments
Keith Stewart et al.
We know that MRD is relevant, what next?
An introduction to the HOVON-141 trial in patients with CLL